



PCG DESK



Industry	CMP	Recommendation	Add on dips to	Target	Time Horizon
Agrochemicals	Rs. 801	Buy at CMP and add on Dips	Rs. 801-740	Rs. 988	4 Quarters

HDFC Scrip Code	UNIPHO
BSE Code	512070
NSE Code	UPL
Bloomberg	UPLL IN
CMP as on 19 Jan'18	801
Equity Capital (Rsmn)	1017
Face Value (Rs)	2
Equity O/S (mn)	508
Market Cap (Rs mn)	4,07,473
Book Value (Rs)	145
Avg. 52 Week Vol	1519193
52 Week High	902
52 Week Low	680

Shareholding Pattern (%)				
Promoters	27.9			
Institutions	51.7			
Non Institutions	20.5			

PCG Risk Rating*	Yellow
* Refer Rating explanation	

FUNDAMENTAL ANALYST Nisha Sankhala

nishaben.shankhala@hdfcsec.com

Incorporated in 1969, United Phosphorus Ltd. is a global generic crop protection, chemicals and seeds company. The company manufactures and markets agrochemicals, industrial chemicals, chemical intermediates, and specialty chemicals in 130+ countries across all six continents. The Company's segments include Agro activity and Non-agro activity. The Agro activity segment includes the manufacturing and marketing of conventional agrochemical products, seeds and other agricultural related products. The Non-agro activity segment includes the manufacturing and marketing of industrial chemicals and other non-agriculture related products. It offers products like fungicides, herbicides, insecticides, plant growth and regulators, rodenticides, industrial and specialty chemicals, and nutrifeeds. The Company sells its products in approximately 130 countries. It has 14 Manufacturing units in India and 19 outside India.

We recommend UPL as a Buy at CMP of Rs. 801 and add on decline of Rs. 740 for the target of Rs.988 (18x of FY20 EPS) for the time frame of 4 Quarters.

Investment Rationale:

Dominant Player in the High Entry Barrier Industry

India is the fourth largest global producer of agrochemicals in the world after US, Japan and China. This segment generated a value of US \$4.4bn in FY15 and is expected to grow at 7.5% per annum to reach US \$6.3bn by FY20.

UPL is the 2rd largest post-patent crop protection chemical company and the 9th largest agrochemical company in the world. It has done 25+ acquisitions in more than two decades of time. Acquisitions were done to gain access to the overseas markets, and to increase their distribution, brands and registrations. Most of these acquisitions were turned around successfully and boosted UPL's presence globally.

Crop protection market is a mature industry and has very high entry barriers because of three key factors, high upfront investments, high R&D Cost and strict regulations. Companies have to incur huge capex for plants, machinery etc. before they see any sales in this industry. Even the R&D cost for the development of new products is quite high for this industry. The overall process of product registration in various geographies remains tedious and time-consuming. For instance, in the USA, it takes 3-3.5 years to register a product. Europe and Japan have even longer periods for product registration with 4-5 years and 8-9 years respectively.

PICK OF THE WEEK Jan 22, 2018

KEY HIGHLIGHTS

• UPL Ltd is a global agrochemical company catering to crop protection chemical, seeds and post-harvest products.

HDFC securities

- UPL is the Dominant Player in the High Entry Barrier Industry.
- Company has superior & innovative product and wider geographic range.
- Budget is likely to focus more on Agri sector
- UPL is consistently outperforming the global crop protection chemical industry for the last five consecutive years.
- UPL has cost advantage over other peers because of backward integration.
- We recommend UPL as a Buy at CMP of Rs. 801 and add on decline of Rs. 740 for the target of Rs.988 (18x of FY20 EPS).

Superior & Innovative product and wider geographic range

UPL is not just a product driven company; over the period of time company has evolved itself as servicedriven organization. The company is now a one stop solution for farmers in their all agriculture related needs. It has presence in manufacturing seed, protecting seeds and post-harvest storage solutions also. UPL has 5934 of product registrations across countries. It not only manufactures and markets agrochemicals but also industrial chemicals, chemical intermediates, and specialty.

UPL is constantly doing R&D for developing new and innovative product. It has shown tremendous progress improving its product mix over the past few years, with innovation rate rising form 2.5% in FY14 to 15% in FY17.

The Company sells its products in approximately 130 countries. It has 14 Manufacturing units in India and 19 outside India. Almost 80% of the revenue comes from Outside India. Regions of Latin America, Europe, and the North America continue to remain largest markets outside India. This helps company in getting balanced revenue throughout the year and reduces the risk of fluctuating demand from any one region.

Presence across value chain:





Budget Expectations

HDFC securities

The agriculture sector in India is expected to perform better in the next few years due to increased investments in agricultural infrastructure such as irrigation facilities, warehousing and cold storage. Government will continue to push for doubling the farm income. Almost every year the Union Budget brings some cheer for the Agriculture sector. Last year provisions for crop insurance, Agri-credit loan, micro Irrigation Fund etc. were introduced giving an added boost to the sector. Overall support to agriculture sector was raised by 24% to Rs.1.87trn.

This year, the expectation from the Union Budget is that it may announce a number of proposals which will result to an improvement in the credit flow to farmers, an increase in irrigation acreage, crop insurance and a boost to farm incomes. With these measures, the income of farmers will increase leaving them with higher disposable income and this in turn will benefit all agri-input companies like UPL.

Cost Advantage via Backward Integration

China is the largest producer of raw materials used in the agro chemicals. But now due to increasingly stringent environmental norms in China their supply to the global market is reducing. 60-65% of manufacturing takes place in-house for UPL giving it a significant advantage over other industry players who are dependent on China as a supplier of raw materials.

Strong Financials

UPL is consistently outperforming the global crop protection chemical industry for the last five consecutive years. This year also it has outperformed the global crop protection chemical industry by reporting a revenue growth of 17% against the broad sectors de-growth of 2.5%. This outperformance is remarkable considering that the overall sector posted its second consecutive de-growth year.

In FY17, Company has posted excellent numbers. Sales rose 16%, EBITDA grew 24.6% while Net Profit jumped 73% aided by other income. Going ahead we expect UPL to post a growth of 13% in revenue and 15% in PAT and CAGR over FY17-20E and margin to increase 100bps over the same period of time. Net D/E is expected to reach 0.1x in FY20E from c.0.4x.

Jan 22, 2018



View & Valuation:

UPL remains the preferred pick among the industry because of Superior & Innovative product and wider geographic range, Stable working capital cycle and cost advantage via of Backward Integration. Populist budget will focus more on Agri sector and this in turn will bust demand for UPL's products.

UPL is consistently outperforming the global crop protection chemical industry for the last five consecutive years. It has been included in the prestigious NSE's Nifty 50 index from 29th September 2017.

We recommend UPL as a Buy at CMP of Rs. 801 and add on decline of Rs. 740 for the target of Rs.988 (18x of FY20 EPS) for the time frame of 4 Quarters.

Risk & Concerns:

- > Almost 80% of the revenue comes from overseas so currency fluctuation might hurt the profitability.
- > Agriculture sector is always influenced by the politics and any regulatory changes might hurt or can give benefit to company.
- > The majority of the suppliers of the industry are from China. They are witnessing capacity cuts. So the fluctuation of raw material prices might be seen in near future.

Quarterly Financials Snapshot (Consolidated)

(Rs mn)	2QFY18	2QFY17	YoY (%)	1QFY18	QoQ (%)
Net Sales	37,700	35,410	6.5	37,230	1.3
Material Expenses	16,560	16,490	0.4	16,470	0.5
Employee Expenses	4,460	3,990	11.8	4,120	8.3
Other Expenses	9,910	9,450	4.9	9,730	1.8
EBITDA	6,770	5,480	23.5	6,910	(2.0)
Depreciation	1,650	1,540	7.1	1,580	4.4
EBIT	5,120	3,940	29.9	5,330	(3.9)
Other Income	760	820	(7.3)	1,010	(24.8)
Interest	1,820	1,800	1.1	800	127.5
РВТ	4,060	2,960	37.2	5,540	(26.7)
Тах	750	430	74.4	480	56.3
РАТ	3,310	2,530	30.8	5,060	(34.6)
Minority Interest/Associate	620	310	100.0	120	416.7
RPAT	2,690	2,220	21.2	4,940	(45.5)
AEPS (Rs/sh)	4.7	3.3	43.4	9.3	(49.9)

Source: Company, HDFC sec Research


Segmental Revenues

HDFC securities

	2QFY18	2QFY17	YoY (%)	1QFY18	QoQ (%)
North America	3,930	3,750	4.8	6,810	(42.3)
India	9,970	9,090	9.7	12,460	(20.0)
Europe	3,630	3,410	6.5	5,850	(37.9)
RoW	6,320	5,990	5.5	6,020	5.0
Latin America	13,850	13,170	5.2	7,370	87.9
Total	37,700	35,410	6.5	38,510	(2.1)




Well diversified and strong product portfolio (FY17)




Source: Company, HDFC sec Research

Innovation rates (sales of new products/ overall sales)




Revenue Break up geographiy wise (FY17)




Source: Company, HDFC sec Research

Number of Product Registrations




Revenue may see~ 5% CAGR over FY17-20E




Source: Company, HDFC sec Research

EBITDA and EBITDA Margin




Source: Company, HDFC sec Research

Declining Trend of Net Debt to Equity



Source: Company, HDFC sec Research

Retrun Ratios



Income Statement (Consolidated)

Ľ

HDFC securities

(Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
Net Sales	1,40,480	163,120	178,210	202,233	232,381
Growth (%)	16.2	16.1	9.3	13.5	14.9
Material Expenses	67,800	78,160	85,095	98,083	113,867
Employee Expenses	14,340	16,270	17,897	20,224	23,257
Other Operating Expenses	34,390	38,840	41,629	45,684	50,694
EBIDTA	23,950	29,850	33,589	38,242	44,563
EBIDTA Margin (%)	17.0	18.3	18.8	18.9	19.2
EBIDTA Growth (%)	1.4	24.6	12.5	13.9	16.5
Depreciation	6,760	6,720	6,994	7,260	7,489
EBIT	17,190	23,130	26,594	30,982	37,074
Other Income	1,870	3,630	3,552	3,670	3,750
Interest & Financial Charges	7,040	7,350	6,526	6,286	6,139
PBT	12,020	19,410	23,620	28,366	34,685
Тах	1,650	1,890	4,724	5,673	6,937
RPAT	10,370	17,520	18,896	22,693	27,748
Profit From Associates	(850)	(190)	(590)	(390)	(190)
EO (Loss) / Profit (Net Of Tax)	(903)	(731)	-	-	-
АРАТ	10,423	18,061	18,306	22,303	27,558
APAT Growth (%)	(9.4)	73.3	1.4	21.8	23.6
AEPS	20.4	35.4	35.9	43.7	54.0
AEPS Growth (%)	(9.4)	73.3	1.4	21.8	23.6

Source: Company, HDFC sec Research

Balance Sheet (Consolidated)

(Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
SOURCES OF FUNDS					
Share Capital	860	1,010	1,020	1,020	1,020
Reserves	58,030	72,960	86,595	104,235	126,030
Total Shareholders Funds	58,890	73,970	87,615	105,255	127,050
Minority Interest	440	330	240	240	240
Long-term Debt	22,660	53,500	52,000	50,500	49,000
Short-term Debt	25,050	7,080	5,580	4,080	2,580
Total Debt	47,710	60,580	57,580	54,580	51,580
Long-term Provisions & Others	5,020	4,040	4,040	4,040	4,040
TOTAL SOURCES OF FUNDS	1,12,060	138,920	149,475	164,115	182,910
APPLICATION OF FUNDS					
Net Block	34,450	36,520	37,446	41,186	44,697
CWIP	4,840	7,920	11,000	11,000	11,000
Goodwill on Consolidation	4,170	4,190	4,190	4,190	4,190
Investments	3,350	3,780	3,780	3,780	3,780
LT Loans & Advances	5,910	7,720	7,720	7,720	7,720
Inventories	37,870	41,560	43,942	49,866	57,299
Debtors	51,000	56,560	61,031	69,258	79,582
Cash & Equivalents	11,890	28,950	33,604	37,592	44,204
ST Loans & Advances	2,700	1,190	1,190	1,190	1,190
Other Current Assets	8,610	8,720	8,720	8,720	8,720
Current Assets	1,12,070	136,980	148,487	166,626	190,996
Creditors	39,540	48,750	53,707	60,947	70,033
Other Current Liabilities & Provi	17,090	14,450	14,450	14,450	14,450
Current Liabilities	56,630	63,200	68,157	75,397	84,483
Net Current Assets	55,440	73,780	80,330	91,229	106,513
Net Deferred Tax Asset	3,900	5,010	5,010	5,010	5,010
TOTAL APPLICATION OF FUNDS	1,12,060	138,920	149,475	164,115	182,910

HDFC securities

UPL Limited

Cash Flow Statement (Consolidated)

Ľ

(Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
Reported PBT	13,310	20,220	23,620	28,366	34,685
Non-operating & EO Items	(1,690)	(2,980)	(3,552)	(3,670)	(3,750)
Interest Expenses	7,040	7,350	6,526	6,286	6,139
Depreciation	6,760	6,720	6,994	7,260	7,489
Working Capital Change	(7,040)	(1,210)	(1,896)	(6,911)	(8,673)
Tax Paid	(4,420)	(3,410)	(4,724)	(5,673)	(6,937)
OPERATING CASH FLOW (a)	13,960	26,690	26,969	25,658	28,953
Capex	(10,140)	(12,590)	(12,000)	(12,000)	(12,600)
Free Cash Flow (FCF)	3,820	14,100	14,969	13,658	16,353
Investments	(660)	(430)	-	-	-
Non-operating Income	3,160	4,440	3,552	3,670	3,750
Others	(9,550)	(1,410)	-	-	-
INVESTING CASH FLOW (b)	(17,190)	(9,990)	(8,448)	(8,330)	(8,850)
Debt Issuance/(Repaid)	12,840	10,790	(3,000)	(3,000)	(3,000)
Interest Expenses	(7,040)	(7,350)	(6,526)	(6,286)	(6,139)
FCFE	9,620	17,540	5,442	4,372	7,214
Share Capital Issuance	-	-	10	-	-
Dividend	(2,290)	(2,280)	(4,391)	(4,664)	(5,762)
Others	1,030	(830)	(10)	0	0
FINANCING CASH FLOW (c)	4,540	330	(13,917)	(13,949)	(14,902)
NET CASH FLOW (a+b+c)	1,310	17,030	4,604	3,379	5,202
EO Items, Others	(440)	30	-	-	-
Closing Cash & Equivalents	11,890	28,950	33,604	37,592	44,204

Source: Company, HDFC sec Research

Key Ratios

	FY16	FY17	FY18E	FY19E	FY20E
PROFITABILITY (%)					
GPM	51.7	52.1	52.3	51.5	51.0
EBITDA Margin	17	18.3	18.8	18.9	19.2
APAT Margin	7.4	11.1	10.3	11.0	11.9
RoE	18.5	27.2	22.7	23.1	23.7
RoCE	16	19.7	16.3	17.4	18.7
EFFICIENCY					
Tax Rate (%)	13.7	9.7	20.0	20.0	20.0
Asset Turnover (x)	1.4	1.3	1.2	1.3	1.3
Inventory (days)	98	93	90	90	90
Debtors (days)	133	127	125	125	125
Payables (days)	103	109	110	110	110
Cash Conversion Cycle (days)	113	100	95	99	102
Debt/EBITDA (x)	2	2.0	1.7	1.4	1.2
Net D/E	0.6	0.4	0.3	0.2	0.1
Interest Coverage	2.4	3.1	4.1	4.9	6.0
PER SHARE DATA (Rs/sh)					
EPS	20.4	35.4	35.9	43.7	54.0
CEPS	33.7	48.6	49.6	58.0	68.7
DPS	4.2	6.9	7.0	7.4	9.2
BV	115.5	145.0	171.8	206.4	249.1
VALUATION					
P/E	39	22.5	22.2	18.2	14.7
P/BV	6.9	5.5	4.6	3.9	3.2
ev/ebitda	18.2	15.1	13.2	11.4	9.6
Dividend Yield (%)	0.5	0.8	0.9	0.9	1.1
OCF/EV (%)	3.2	5.9	6.1	5.9	6.8
FCF/EV (%)	0.9	3.1	3.4	3.1	3.8
FCFE/Mcap (%)	(0.8)	1.6	2.0	1.8	2.4



Rating Chart

R	HIGH				
E T U	MEDIUM				
R					
Ν	LOW				
		LOW	MEDIUM	HIGH	
		RISK			

Ratings Explanation:

RATING	Risk - Return	BEAR CASE	BASE CASE	BULL CASE
BLUE	LOW RISK - LOW RETURN STOCKS	IF RISKS MANIFEST PRICE CAN FALL 20% OR MORE	IF RISKS MANIFEST PRICE CAN FALL 15% & IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 15%	IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 20% OR MORE
YELLOW	MEDIUM RISK - HIGH RETURN STOCKS	IF RISKS MANIFEST PRICE CAN FALL 35% OR MORE	IF RISKS MANIFEST PRICE CAN FALL 20% & IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 30%	IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 35% OR MORE
RED	HIGH RISK - HIGH RETURN STOCKS	IF RISKS MANIFEST PRICE CAN FALL 50% OR MORE	IF RISKS MANIFEST PRICE CAN FALL 30% & IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 30%	IF INVESTMENT RATIONALE FRUCTFIES PRICE CAN RISE BY 50% OR MORE





Rating Definition:

Buy: Stock is expected to gain by 10% or more in the next 1 Year.

Sell: Stock is expected to decline by 10% or more in the next 1 Year.



Disclosure:

I, Nisha Sankhala, MBA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or her relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

Any holding in stock -NO

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking, or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.